BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with - 2The most effective method to Go with Informed Choices on Vehicle Leases
- 3These Cities Led Global Jet-Setting In 2025, According To New Data
- 4The most effective method to Pick a Campervan That Offers Something else for Less
- 5Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
- The Effect of Online Organizations on Society: Beating the Difficulties
- The 10 Most Significant Games in History
- The most effective method to Beat Dental Tension and Guarantee Customary Exams
- Fireballs and a full moon. Here’s how to see two celestial events this week
- the Wild in Style: The Reduced Portage Mustang's Bold Heritage
- Top 20 Style Brands for Pioneers
- Norovirus is spreading earlier again this year, wastewater data shows
- Vote in favor of your favored spot to peruse
- Addiction-stricken community struggles to keep a syringe program going after Trump's order
